Cenobamate API

Mecanismo de acción

Cenobamate is a novel antiepileptic drug that acts as a selective modifier of synaptic transmission. It modulates GABAergic neurotransmission by increasing the GABAergic inhibitory drive on neuronal networks.

The precise mechanism of action of cenobamate is not fully understood, but it is believed to work by increasing the release of the neurotransmitter GABA and enhancing the activation of GABA A receptors, which are the major inhibitory receptors in the central nervous system. This results in an increased inhibition of neurons and a reduction of excitability in the brain, which can help to reduce seizures in patients with epilepsy.

In addition to its effect on GABAergic neurotransmission, cenobamate has been shown to have a low affinity for several other neurotransmitter receptors, including glutamate, dopamine, and norepinephrine receptors. These properties may contribute to the drug's ability to improve seizure control in some patients.

Overall, the mechanism of action of cenobamate is believed to involve a combination of effects on GABAergic neurotransmission and modulation of other neurotransmitter receptors, leading to a reduction in seizures in patients with epilepsy.

Indicación

Cenobamate is an FDA-approved antiepileptic drug indicated for the treatment of partial-onset seizures in adults with epilepsy.

Partial-onset seizures are a type of seizure that occurs in a specific part of the brain and can cause a variety of symptoms, including motor changes, sensory alterations, and changes in consciousness.

Cenobamate is intended for use as an adjunctive therapy, meaning that it is used in combination with other antiepileptic drugs to improve seizure control in patients who have not achieved adequate control of their seizures with their current treatment.

It is important to note that cenobamate is not a cure for epilepsy and may not work for all patients. The best course of treatment will depend on the individual patient and should be determined by a healthcare professional.

Experiencia de Dr. Reddy

Con sede en Hyderabad, India, Dr. Reddy's Laboratories es uno de los principales proveedores de ingredientes farmacéuticos activos (API) a nivel mundial. El negocio API de Dr. Reddy es considerado como un socio preferido de las compañías farmacéuticas en los Estados Unidos, Europa, Brasil, América Latina, Japón, China, Corea y los mercados emergentes.

El negocio de API de Dr. Reddy se nutre de las fortalezas técnicas profundas establecidas en los últimos 30 años en el desarrollo y fabricación de API complejas como esteroides, péptidos, moléculas complejas de cadena larga y API altamente potentes (HPAPI / medicamentos oncológicos). Esta experiencia se complementa con nuestra destreza en propiedad intelectual y asuntos regulatorios que nos ayudan a cumplir y superar los estándares regulatorios de manera consistente. Los APIs de Dr. Reddy´s Cenobamate es el resultado de la amplia experiencia en R&D, IP y Normatividad Aplicable.

Un componente clave para ayudar a nuestros clientes a ser los primeros en comercializar es una cadena de suministro receptiva. Logramos esto al asegurarnos de que todas nuestras instalaciones funcionen de manera eficiente y con los últimos estándares de calidad, seguridad y productividad. Una fuerte interconexión entre las empresas y las fábricas permite una reacción rápida a los cambios dinámicos del mercado, de modo que podamos evitar la escasez y satisfacer los repentinos aumentos de la demanda.